PL2095825T3 - Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu - Google Patents

Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu

Info

Publication number
PL2095825T3
PL2095825T3 PL06843990T PL06843990T PL2095825T3 PL 2095825 T3 PL2095825 T3 PL 2095825T3 PL 06843990 T PL06843990 T PL 06843990T PL 06843990 T PL06843990 T PL 06843990T PL 2095825 T3 PL2095825 T3 PL 2095825T3
Authority
PL
Poland
Prior art keywords
tissues
acid content
diseases associated
deoxyribonucleic acid
human diseases
Prior art date
Application number
PL06843990T
Other languages
English (en)
Polish (pl)
Inventor
Dmitry Dmitrievich Genkin
Viktor Veniaminovich Tets
Georgy Viktorovich Tets
Original Assignee
Cls Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cls Therapeutics Ltd filed Critical Cls Therapeutics Ltd
Publication of PL2095825T3 publication Critical patent/PL2095825T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL06843990T 2006-11-28 2006-11-28 Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu PL2095825T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06843990A EP2095825B8 (en) 2006-11-28 2006-11-28 Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
PCT/RU2006/000642 WO2008066403A1 (fr) 2006-11-28 2006-11-28 Procédé de traitement de maladies humaines accompagnées d'une teneur plus élevée d'adn dans des espaces intercellulaires et préparation médicamenteuse destinée à sa mise en oeuvre

Publications (1)

Publication Number Publication Date
PL2095825T3 true PL2095825T3 (pl) 2011-12-30

Family

ID=39468110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06843990T PL2095825T3 (pl) 2006-11-28 2006-11-28 Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu

Country Status (9)

Country Link
US (1) US8871200B2 (enExample)
EP (1) EP2095825B8 (enExample)
JP (1) JP5372769B2 (enExample)
KR (1) KR20090087095A (enExample)
AT (1) ATE513557T1 (enExample)
ES (1) ES2369547T3 (enExample)
IL (1) IL199005A (enExample)
PL (1) PL2095825T3 (enExample)
WO (1) WO2008066403A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
EP2095825B8 (en) 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
SG179188A1 (en) 2009-09-18 2012-04-27 Nippon Kayaku Kk Catalyst and process for preparing acrolein and/or acrylic acid by dehydration reaction of glycerin
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3240896A1 (en) 2015-01-04 2017-11-08 Protalix Ltd. Modified dnase and uses thereof
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
WO2017060493A1 (en) * 2015-10-07 2017-04-13 Novozymes A/S Polypeptides
US20190083636A1 (en) 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2019143272A1 (en) 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity
EP3813555A4 (en) * 2018-06-29 2022-03-30 Tets, Viktor, Veniaminovich COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA
US20200046809A1 (en) * 2018-08-07 2020-02-13 Bradley G. Thompson Methods for regulating endogenous production of dnase1
US20220062146A1 (en) * 2018-12-17 2022-03-03 Dennis C. Mynarcik Compositions and methods for removing dental calculi
US12478571B2 (en) 2018-12-17 2025-11-25 Pontis Biologics, Inc. Enzyme based compositions and methods for removing dental calculi
CA3194643A1 (en) 2020-10-07 2022-04-14 Ilya Ruderfer Long-acting dnase
CN117999086A (zh) * 2021-05-24 2024-05-07 普利纳斯技术公司 使用dna酶的治疗方案

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
EP0449968B1 (en) * 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
WO1995000170A1 (en) * 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
ATE268605T1 (de) 1994-03-04 2004-06-15 Genentech Inc Pharmazeutische akzeptabel dnase zusammensetzung
AU2455295A (en) 1994-05-20 1995-12-18 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
JP4118334B2 (ja) 1996-02-05 2008-07-16 ジェネンテック・インコーポレーテッド ヒトｄｎアーゼ
AU2324997A (en) 1996-03-15 1997-10-01 Penn State Research Foundation, The Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6524578B1 (en) 1996-07-10 2003-02-25 Scott E. Tackett Use of nuclease to reduce wrinkles and discolorations in humans
US6455250B1 (en) 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
CN1243545C (zh) 1998-07-16 2006-03-01 研究发展基金会 切割dna的抗肿瘤剂
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
JP2002530436A (ja) 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド 増殖能を増強しかつ複製老化を防止する方法及び試薬
JP4522632B2 (ja) * 1999-08-17 2010-08-11 靖一 田沼 新規デオキシリボヌクレアーゼ、それをコードする遺伝子およびそれらの用途
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
AU4430701A (en) 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
DK1549337T3 (en) * 2002-02-18 2014-11-24 Ockham Biotech Ltd COMBINATION OF DNASE I AND GLYCOSAMINOGLYCANES FOR USE IN EXTRACELLULAR DNA CLEARANCE
RU2207676C1 (ru) 2002-04-24 2003-06-27 ООО "Предприятие "Контакт-1" Плоский радиолокационный отражатель
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2005004904A1 (en) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
EP1666055A4 (en) 2003-07-14 2010-02-10 Viktor Veniaminovich Tets METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
JP2007532666A (ja) * 2004-04-14 2007-11-15 アヴィリッド インコーポレーテッド ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法
JP3989936B2 (ja) 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
EP2484768A3 (en) * 2005-07-18 2012-11-21 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
EP2095825B8 (en) 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
US20130243794A1 (en) 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses

Also Published As

Publication number Publication date
IL199005A (en) 2012-04-30
US20100061971A1 (en) 2010-03-11
ATE513557T1 (de) 2011-07-15
EP2095825B1 (en) 2011-06-22
EP2095825B8 (en) 2012-03-28
ES2369547T8 (es) 2012-01-05
WO2008066403A1 (fr) 2008-06-05
EP2095825A1 (en) 2009-09-02
ES2369547T3 (es) 2011-12-01
IL199005A0 (en) 2010-02-17
JP2010511039A (ja) 2010-04-08
US8871200B2 (en) 2014-10-28
KR20090087095A (ko) 2009-08-14
JP5372769B2 (ja) 2013-12-18
EP2095825A4 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
IL199005A0 (en) Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2007095056A3 (en) Slow intraventricular delivery
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
JP2010526857A5 (enExample)
CN116211922B (zh) 一种助眠安神的复方精油及其制备方法与用途
CN100342864C (zh) 治疗顽固性痔疮的内服药
CN102232968A (zh) 治疗脂溢性皮炎的中药外用药酒
WO2007135123A3 (en) Mirtazapine for the treatment of neuropathic pain
CN101757216A (zh) 一种治疗牙痛的中药
CN101167878A (zh) 一种治疗关节炎的药物及其制备方法
CN107029047A (zh) 一种具有活血化瘀、镇痛祛风湿作用的药剂及其药物配方
CN106510890A (zh) 一种家畜口服给药装置及其应用
Lammers et al. Modified Preoperative Oral Dose Acetaminophen vsIntravenous Acetaminophen in Children: ARandomized Clinical Trial
CN101732435A (zh) 治疗口疮的药物组合物
WO2008133952A3 (en) Transmucosal treatment with fentanyl in patients with mucositis
CN105311304A (zh) 一种治疗抑郁症的药物
CN102846670A (zh) 治疗咬手指癖的生物药剂
BRPI0404771A (pt) medicamento e tratamento para dores em geral e outros sintomas